Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Acronyms HAL03T
- Sponsors Eisai Co Ltd
- 11 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.
- 11 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Jan 2019.
- 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.